Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Positive CHMP Opinion for Once-weekly Somatropin Biopartners

Published: Monday, June 03, 2013
Last Updated: Monday, June 03, 2013
Bookmark and Share
Approval of Somatropin Biopartners for the treatment of growth hormone deficiency in paediatric and adult patients.

Biopartners GmbH has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion regarding the approval of once-weekly Somatropin Biopartners for the treatment of growth hormone deficiency (GHD) in paediatric and adult patients.

The CHMP's recommendation is now referred to the European Commission (EC) which grants approval for the European Union, Norway and Iceland. The EC decision is anticipated in the middle of the third quarter of 2013.

Somatropin Biopartners is the first prolonged-release somatropin-containing medicinal product to receive a positive CHMP opinion.

Somatropin Biopartners will allow for a once-weekly subcutaneous injection instead of the currently available therapies that require once-daily injections of growth hormone (GH).

Poor adherence and noncompliance have been identified as a major cause of suboptimal efficacy of current GH replacement therapy in children as well as adults.

The typical symptom of GHD in children is growth failure, and consequently the aim of treatment is the normalization of the growth rate during childhood and attainment of normal adult height.

The clinical features associated with GHD in adults include abdominal obesity, decreased lean body mass, reduced muscle strength and exercise capacity, abnormalities in lipid and cardiovascular markers, decreased bone mineral density and impaired quality of life.

In Phase III comparative trials in children and adults, respectively, which were conducted as part of a joint development programme with LG Life Sciences Ltd., Somatropin Biopartners proved to be safe and effective, showing sustained growth in children and beneficial effects on body composition in adults.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
`Molecular Commando’ Identified to Tackle Hypoxia Pathway
Scientists identify 'molecular commando' that can activate hypoxic response, which helps combat a number of conditions.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Two Antibiotics Fight Bacteria Differently Than Thought
Researchers discover that two widely prescribed antibiotics may fight bacteria differently than previously thought.
Drug Target for Gastrointestinal Stromal Tumors Identified
Researchers show the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!